#ThinkSabio Latest News
monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
$150m upfront, $2.1B milestones
Subscribe
for ThinkSabio Updates !
We'll keep you up to date about our Stocks, Sec Alerts , Trendings Stocks etc..